%0 Journal Article %T Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features %+ Service d'Hématologie [CHU Poitiers] %+ Service Hématologie - IUCT-Oncopole [CHU Toulouse] %+ CHU de Lille, Service des maladies du sang %+ Centre de Recherches en Cancérologie de Toulouse (CRCT) %+ Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037) %+ Institut de Systématique, Evolution, Biodiversité (ISYEB ) %+ Hôpital Haut-Lévêque [CHU Bordeaux] %+ CHU Amiens-Picardie %+ HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 (HEMATIM) %+ Centre Hospitalier Chalon-sur-Saône William Morey %+ Hôpital Henri Mondor %+ Service d'Hématologie [CHRU Nancy] %+ Avignon Université (AU) %+ Hôpital Avicenne [AP-HP] %+ CHU Caen %+ Service d’Hématologie [Institut Paoli Calmettes, Marseille] %+ Centre Hospitalier Saint Jean de Perpignan %+ Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois] %+ Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon) %+ Service d'Hématologie Clinique (CHU de Dijon) %+ Hôpital Claude Huriez [Lille] %+ CHU Saint-Antoine [AP-HP] %+ Centre de Recherche Saint-Antoine (CRSA) %+ Centre Hospitalier Universitaire de Toulouse (CHU Toulouse) %A Cazaubiel, Titouan %A Leleu, Xavier %A Perrot, Aurore %A Manier, Salomon %A Buisson, Laure %A Maheo, Sabrina %A Ferreira, Laura Do Souto %A Lannes, Romain %A Pavageau, Luka %A Hulin, Cyrille %A Marolleau, Jean-Pierre %A Voillat, Laurent %A Belhadj, Karim %A Divoux, Marion %A Slama, Borhane %A Brechignac, Sabine %A Macro, Margaret %A Stoppa, Anne-Marie %A Sanhes, Laurence %A Orsini-Piocelle, Frederique %A Fontan, Jean %A Chretien, Marie-Lorraine %A Demarquette, Helene %A Mohty, Mohamad %A Schavgoulidze, Anais %A Avet-Loiseau, Herve %A Corre, Jill %< avec comité de lecture %@ 0006-4971 %J Blood %I American Society of Hematology %V 139 %N 17 %P 2666-2672 %8 2022 %D 2022 %R 10.1182/blood.2021014968 %Z Life Sciences [q-bio]Journal articles %X Primary plasma cell leukemia (pPCL) is an aggressive form of multiple myeloma (MM) that has not benefited from recent therapeutic advances in the field. Because it is very rare and heterogeneous, it remains poorly understood at the molecular level. To address this issue, we performed DNA and RNA sequencing of sorted plasma cells from a large cohort of 90 newly diagnosed pPCL and compared with MM. We observed that pPCL presents a specific genomic landscape with a high prevalence of t(11;14) (about half) and high-risk genomic features such as del(17p), gain 1q, and del(1p32). In addition, pPCL displays a specific transcriptome when compared with MM. We then wanted to characterize specifically pPCL with t(11;14). We observed that this subentity displayed significantly fewer adverse cytogenetic abnormalities. This translated into better overall survival when compared with pPCL without t(11;14) (39.2 months vs 17.9 months, P 5 .002). Finally, pPCL with t(11;14) displayed a specific transcriptome, including differential expression of BCL2 family members. This study is the largest series of patients with pPCL reported so far. %G English %L hal-03684088 %U https://u-picardie.hal.science/hal-03684088 %~ MNHN %~ UNIV-AVIGNON %~ EPHE %~ UNIV-TLSE3 %~ UNIV-AG %~ CNRS %~ UNIV-PICARDIE %~ APHP %~ U938 %~ ISYEB %~ COMUE-NORMANDIE %~ PSL %~ SORBONNE-UNIVERSITE %~ SORBONNE-UNIV %~ SU-MEDECINE %~ SU-SCIENCES %~ TEST-DEV %~ SU-MED %~ EPHE-PSL %~ SU-TI %~ U-PICARDIE %~ HEMATIM %~ ALLIANCE-SU %~ UNIV-UT3 %~ UT3-INP %~ UT3-TOULOUSEINP %~ TEST3-HALCNRS %~ TEST4-HALCNRS %~ CRCT %~ TEST5-HALCNRS